EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology

Melania Gaggini, Laura Sabatino iD, Adrian Florentin Suman, Kyriazoula Chatzianagnostou, Cristina Vassalle iD

Cells · 06.03.2025 · 14 (5) · 387

DOI: 10.3390/cells14050387 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 06.03.2025. Verfasst von Melania Gaggini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Physiology, National Research Council, Via G. Moruzzi 1, 56124 Pisa, Italy. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Dipeptidyl Peptidase 4, Sodium-Glucose Transporter 2, Kidney. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 153 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, new drugs for the treatment of type 2 diabetes (T2D) have been proposed, including glucagon-like peptide 1 (GLP-1) agonists or sodium–glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. Over time, some of these agents (in particular, GLP-1 agonists and SGLT2 inhibitors), which were initially developed for their glucose-lowering actions, have demonstrated significant beneficial pleiotropic effects, thus expanding their potential therapeutic applications. This review aims to discuss the mechanisms, pleiotropic effects, and therapeutic potential of GLP-1, DPP-4, and SGLT2, with a particular focus on their cardiorenal benefits beyond glycemic control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1Dipeptidyl Peptidase 4Sodium-Glucose Transporter 2KidneyCardiovascular DiseasesCardiovascular SystemHumansDiabetes Mellitus, Type 2AnimalsDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 Inhibitors

Stichwörter der Autor:innen

cardiorenal systemdipeptidyl peptidase-4 inhibitorsglucagon-like peptide 1 agonistsglycemic controlsodium–glucose cotransporter 2 inhibitorstype 2 diabetes

Substanzen

Glucagon-Like Peptide 1Dipeptidyl Peptidase 4Sodium-Glucose Transporter 2Dipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Institute of Clinical Physiology, National Research Council, Via G. Moruzzi 1, 56124 Pisa, Italy.
  • Fondazione CNR-Regione Toscana G Monasterio, Via G. Moruzzi 1, 56124 Pisa, Italy.

ORCID-Profile: Laura Sabatino, Cristina Vassalle

Zitieren

APA

Gaggini, M., Sabatino, L., Suman, A. F., Chatzianagnostou, K., & Vassalle, C. (2025). Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology. Cells, 14(5), 387. https://doi.org/10.3390/cells14050387

Vancouver

Gaggini M, Sabatino L, Suman AF, Chatzianagnostou K, Vassalle C. Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology. Cells. 2025;14(5):387. doi:10.3390/cells14050387

BibTeX
@article{Gaggini2025,
  author = {Gaggini, Melania and Sabatino, Laura and Suman, Adrian Florentin and Chatzianagnostou, Kyriazoula and Vassalle, Cristina},
  title = {Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {5},
  pages = {387},
  doi = {10.3390/cells14050387}
}
Kostenlos starten →